Medicare Enrolled
Dr. Shadi Latta, M.D.
Hematology & Oncology · Tinley Park, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Latta from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Latta?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Latta
Dr. Shadi Latta is a hematology & oncology specialist in Tinley Park, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Latta performed 97,112 Medicare services across 1,942 unique beneficiaries.
Between the years covered by Open Payments, Dr. Latta received a total of $17,898 from 82 pharmaceutical and/or device companies across 581 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Latta is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 11% volume in IL
$17,898 industry payments
Medicare Practice Summary
Medicare Utilization ↗97,112
Medicare services
Top 11% in IL for hematology & oncology
1,942
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,111 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
41,550 | $2 | $21 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
30,750 | $1 | $5 |
| Pembrolizumab injection (Keytruda) | 9,000 | $43 | $146 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,600 | $0 | $7 |
| Denosumab injection (Prolia/Xgeva) | 3,000 | $19 | $71 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,257 | $0 | $3 |
| Anti-nausea injection (Aloxi/palonosetron) | 610 | $1 | $122 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
446 | $69 | $270 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
439 | $66 | $270 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
430 | $2 | $300 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
345 | $99 | $399 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
343 | $11 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
279 | $108 | $686 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
272 | $13 | $105 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
216 | $83 | $1,444 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
184 | $145 | $747 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
172 | $99 | $376 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
166 | $143 | $530 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
152 | $24 | $152 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
90 | $55 | $205 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
88 | $1 | $7 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
82 | $23 | $156 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
70 | $54 | $334 |
| New patient office visit, complex (60-74 min) | 62 | $168 | $760 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
60 | $51 | $304 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
59 | $0 | $3 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
58 | $94 | $467 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
52 | $29 | $240 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
50 | $1 | $8 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
47 | $263 | $758 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
45 | $1 | $19 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
35 | $1,298 | $4,120 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 35 | $414 | $638 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
34 | $16 | $91 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
34 | $112 | $620 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.3% high complexity
65.7% medium
2.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,898
Total received (2018-2024)
Avg $2,557/year across 7 years
Top 22% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
82
Companies
581
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,013 (61.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,658 (20.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,227 (18.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,658
2023
$4,146
2022
$1,634
2021
$1,671
2020
$1,158
2019
$2,789
2018
$3,843
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$209
Regeneron Healthcare Solutions, Inc.
$209
Incyte Corporation
$190
Novartis Pharmaceuticals Corporation
$183
GlaxoSmithKline, LLC.
$160
Takeda Pharmaceuticals U.S.A., Inc.
$153
AstraZeneca Pharmaceuticals LP
$144
Merck Sharp & Dohme LLC
$137
Janssen Biotech, Inc.
$133
Alexion Pharmaceuticals, Inc.
$128
Gilead Sciences, Inc.
$87
E.R. Squibb & Sons, L.L.C.
$85
Astellas Pharma US Inc
$82
Genentech USA, Inc.
$71
ABBVIE INC.
$46
Tempus AI, Inc
$46
Eisai Inc.
$45
SOBI, INC
$43
TerSera Therapeutics LLC
$38
Pharmacosmos Therapeutics Inc.
$38
Celgene Corporation
$32
Mirati Therapeutics, Inc.
$32
Kite Pharma, Inc.
$30
Daiichi Sankyo Inc.
$29
JAZZ PHARMACEUTICALS INC.
$29
GE HEALTHCARE
$29
Genmab U.S., Inc.
$28
Lilly USA, LLC
$27
Exelixis Inc.
$26
Adaptive Biotechnologies Corporation
$26
Amneal Pharmaceuticals LLC
$26
Bayer Healthcare Pharmaceuticals Inc.
$24
Rigel Pharmaceuticals, Inc.
$21
EMD Serono, Inc.
$20
PUMA BIOTECHNOLOGY, INC.
$19
BeiGene USA, Inc.
$16
ImmunoGen, Inc.
$16
Top 3 companies account for 22.9% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$2,807
AMAG Pharmaceuticals, Inc.
$2,659
Janssen Biotech, Inc.
$2,181
E.R. Squibb & Sons, L.L.C.
$750
Novartis Pharmaceuticals Corporation
$621
Incyte Corporation
$615
PFIZER INC.
$609
Merck Sharp & Dohme Corporation
$580
Amgen Inc.
$473
Genentech USA, Inc.
$469
Merck Sharp & Dohme LLC
$463
Takeda Pharmaceuticals U.S.A., Inc.
$348
Gilead Sciences, Inc.
$308
Regeneron Healthcare Solutions, Inc.
$292
Lilly USA, LLC
$263
GlaxoSmithKline, LLC.
$234
Pharmacyclics LLC, An AbbVie Company
$227
Exelixis Inc.
$193
GENZYME CORPORATION
$183
Seagen Inc.
$180
EMD Serono, Inc.
$167
Astellas Pharma US Inc
$148
Janssen Scientific Affairs, LLC
$144
Alexion Pharmaceuticals, Inc.
$142
Eisai Inc.
$138
Boehringer Ingelheim Pharmaceuticals, Inc.
$127
Celgene Corporation
$126
Bayer HealthCare Pharmaceuticals Inc.
$125
Rigel Pharmaceuticals, Inc.
$110
JAZZ PHARMACEUTICALS INC.
$110
G1 Therapeutics, Inc.
$105
BeiGene USA, Inc.
$96
Dova Pharmaceuticals
$93
AbbVie, Inc.
$92
ABBVIE INC.
$90
Puma Biotechnology, Inc.
$86
Daiichi Sankyo Inc.
$80
TerSera Therapeutics LLC
$76
Kite Pharma, Inc.
$75
Sobi, Inc
$73
Janssen Pharmaceuticals, Inc
$62
Mirati Therapeutics, Inc.
$50
Pharmacyclics LLC, an AbbVie Company
$47
GE HEALTHCARE
$47
Tempus AI, Inc
$46
MorphoSys, US Inc.
$46
Coherus Biosciences Inc.
$45
Myriad Genetic Laboratories, Inc.
$44
Bayer Healthcare Pharmaceuticals Inc.
$44
SOBI, INC
$43
Pharmacosmos Therapeutics Inc.
$38
Myovant Sciences Inc.
$37
Otsuka America Pharmaceutical, Inc.
$37
TESARO, Inc.
$37
ARRAY BIOPHARMA INC
$35
Foundation Medicine, Inc.
$29
Genmab U.S., Inc.
$28
Fortovia Therapeutics, Inc.
$28
Prometheus Laboratories Inc.
$27
Sumitomo Pharma America, Inc.
$27
Kyowa Kirin, Inc.
$26
Adaptive Biotechnologies Corporation
$26
Amneal Pharmaceuticals LLC
$26
Synergy Pharmaceuticals Inc
$25
Dendreon Pharmaceuticals LLC
$25
Ipsen Biopharmaceuticals, Inc
$24
EUSA Pharma (US) LLC
$23
AbbVie Inc.
$21
Acrotech Biopharma LLC
$20
Epizyme, Inc.,
$20
PUMA BIOTECHNOLOGY, INC.
$19
Karyopharm Therapeutics Inc.
$19
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$19
Array BioPharma Inc.
$19
CTI BioPharma Corp.
$19
Clovis Oncology, Inc.
$18
Seattle Genetics, Inc.
$18
EISAI INC.
$17
ImmunoGen, Inc.
$16
Advanced Accelerator Applications
$14
Helsinn Therapeutics (U.S.), Inc.
$14
GE HealthCare
$13
Top 3 companies account for 42.7% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · AKYNZEO · ALIMTA · ALUNBRIG · AVASTIN · Alecensa · Aliqopa · Avastin · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CREON · CYRAMZA · Cabometyx · Columvi · DARZALEX · DIFICID · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · HEMADY · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · IMJUDO · INJECTAFER · INLYTA · Imbruvica · Itovebi · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · Lutathera · MEKINIST · MONJUVI · MYRISK · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Pomalyst · Prolia · REBLOZYL · RECOTHROM · RYBREVANT · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · Soltamox · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIVDAK · TUKYSA · Tavalisse · Trodelvy · Trulance · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VONJO · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XIFAXAN · XPOVIO · XTANDI · Xermelo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (62%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
239
Per 100K population
4.6
County median income
$81,797
Nearest hospital
PALOS COMMUNITY HOSPITAL
7.1 mi
7.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Latta is a mixed practice specialist, with above-average Medicare volume (top 11% in IL), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Latta experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Latta performed 41,550 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Latta receive payments from pharmaceutical companies?
Yes. Dr. Latta received a total of $17,898 from 82 companies across 581 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Latta's costs compare to other hematology & oncology specialists in Tinley Park?
Dr. Latta's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Latta) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Tinley Park
Browse hematology & oncology specialists in Tinley Park ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
AMAG Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from AMAG Pharmaceuticals, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology